{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:04:56Z","timestamp":1792821896012,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"8b","license":[{"start":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T00:00:00Z","timestamp":1335744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>The interaction between the TRPV1 and NGF systems has been addressed only in the context of acute somatic pain. The present study expands this view and indicates that this interaction remains operative and is important as a mechanism for chronic visceral pain and dysfunction. Moreover, it further stresses the need to develop more specific and effective TRPV1 antagonists for clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>To explore the role of transient receptor potential vanilloid 1 (TRPV1) in the excitatory effects of chronic administration of nerve growth factor (NGF) on bladder\u2010generated sensory input and reflex activity.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>To explore new therapeutic targets for bladder dysfunction.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Wild\u2010type (WT) and TRPV1 knockout (KO) mice received daily intraperitoneal injections of NGF (1\u2003\u00b5g\/10\u2003g) or saline for a period of 4 days, during which time thermal sensitivity was evaluated daily. On the 5th day, mice were anaesthetized and cystometries were performed. The frequency, amplitude and area under the curve (AUC) of bladder reflex contractions were determined.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>c\u2010Fos expression was evaluated on L6 spinal cord sections of WT and TRPV1 KO mice treated with saline or chronic NGF by immunohistochemistry.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>TrkA receptor staining intensity was determined in L6 spinal cord sections and respective dorsal root ganglia of WT and TRPV1 KO mice.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Repeated administration of NGF induced thermal hypersensitivity in WT but not in TRPV1 KO mice.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The frequency of bladder contractions of saline\u2010treated WT and TRPV1 KO mice was similar, the values respectively being 0.45 \u00b1 0.12\/min and 0.46 \u00b1 0.16\/min. Treatment with NGF enhanced bladder reflex activity in WT mice to 1.23 \u00b1 0.41\/min (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.05). In NGF\u2010treated KO mice, the frequency of bladder contractions was 0.60 \u00b1 0.05\/min. Irrespective of treatment, no differences were observed in the amplitude of bladder contractions of WT and TRPV1 KO mice. The AUC was significantly increased in NGF\u2010treated WT\u2010mice, when compared with saline\u2010treated WT\u2010mice. No changes were found in AUC of saline\u2010treated and NGF\u2010treated TRPV1 KO mice.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Chronic administration of NGF resulted in a significant increase of spinal c\u2010Fos expression in WT mice (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.05 vs KO animals), but not in TRPV1 KO animals.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>TrkA expression was similar in WT and TRPV1 KO mice.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>NGF\u2010induced bladder overactivity and noxious input depend on the interaction of NGF with TRPV1.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The lack of bladder overactivity in TRPV1 KO mice treated with NGF does not represent loss of TrkA expression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>TRPV1 is essential for NGF\u2010driven bladder dysfunction and represents a bottleneck target in bladder pathologies associated with NGF up\u2010regulation.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11187.x","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T04:50:09Z","timestamp":1335761409000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Transient receptor potential vanilloid 1 mediates nerve growth factor\u2010induced bladder hyperactivity and noxious input"],"prefix":"10.1111","volume":"110","author":[{"given":"Barbara","family":"Frias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Charrua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia D.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,30]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.046"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.03.074"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000169481.42259.54"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07151.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.29.051605.112929"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.10447"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/83.3.442"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.14.7693"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6793-7-9"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.01.001"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(96)02993-4"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/35082088"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03171-2"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21022"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2893-04.2004"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.039990"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.03893.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.05.015"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-16499-6_17"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/39807"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e32830f1e73"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn902"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2011.09.005"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.12.088"},{"key":"e_1_2_8_27_2","first-page":"94","article-title":"Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain","volume":"12","author":"Cattaneo A","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208783330754"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2006.09.001"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11187.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11187.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:45:59Z","timestamp":1761756359000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11187.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,30]]},"references-count":28,"journal-issue":{"issue":"8b","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11187.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11187.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,30]]},"assertion":[{"value":"2012-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}